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1. INTRODUCTION {#mgg31144-sec-0005}
===============

Congenital myasthenic syndrome 22 (CMS22, OMIM 616,224) is a rare autosomal recessive disorder, characterized by severe neonatal hypotonia, muscular weakness, feeding difficulties, growth hormone deficiency, and childhood obesity (Engel, Shen, Selcen, & Sine, [2015](#mgg31144-bib-0005){ref-type="ref"}). CMS22 is due to homozygous or compound heterozygous mutation in the *PREPL* gene (OMIM 609,557), which encodes a serine oligopeptidase involved in the filling of acetylcholine (ACh) into synaptic vesicles (Jaeken et al., [2006](#mgg31144-bib-0006){ref-type="ref"}). Patients with CMS22 also present with facial weakness (ptosis and tented upper lip), motor developmental delay, and cognitive deficiency (Regal et al., [2018](#mgg31144-bib-0015){ref-type="ref"}, [2014](#mgg31144-bib-0016){ref-type="ref"}). The patient had favorable response to pyridostigmine in infancy and may improve spontaneously after 1 year old (Engel, [2018](#mgg31144-bib-0004){ref-type="ref"}). Regal et al. ([2014](#mgg31144-bib-0016){ref-type="ref"}) reported that they treated three identified patients at 1, 11, and 12 years old with pyridostigmine. Only the infant improved, the two elder children did not respond to pyridostigmine. To date, eight patients with CMS22 have been reported previously, among which there are eight different truncating mutations and six gross deletions of *PREPL* gene (Laugwitz et al., [2018](#mgg31144-bib-0010){ref-type="ref"}; Regal et al., [2018](#mgg31144-bib-0015){ref-type="ref"}, [2014](#mgg31144-bib-0016){ref-type="ref"}; Silva, Miyake, Tapia, & Matsumoto, [2018](#mgg31144-bib-0018){ref-type="ref"}).

Uniparental disomy (UPD) is the inheritance of segmental or total a homologous pair of chromosomes from only one parent (Siegel & Slavotinek, [2005](#mgg31144-bib-0017){ref-type="ref"}). The patient with UPD may be involved in autosomal‐recessive disorders, which unmasks the rare pathogenic variants (Carmichael, Shen, Nguyen, Hirschhorn, & Dauber, [2013](#mgg31144-bib-0003){ref-type="ref"}; Labrijn‐Marks et al., [2019](#mgg31144-bib-0009){ref-type="ref"}). However, maternal UPD of chromosome 2 (UPD(2)mat) with a homozygous pathogenic mutation in *PREPL* has not been reported before.

Here, we report the first case that UPD(2)mat renders a novel homozygous frameshift mutation in *PREPL* causing CMS22 features. Meanwhile, we review the clinical and genetic features of CMS22, which further delineate the phenotype and genotype of CMS22.

2. MATERIALS AND METHODS {#mgg31144-sec-0006}
========================

2.1. Molecular analysis {#mgg31144-sec-0007}
-----------------------

Genomic DNA was extracted from the infant\'s peripheral blood and her parents using a whole blood genomic DNA extraction kit (Qiagen, German). DNA fragments were enriched using the Agilent SureSelect XT Human All Exon 50 Mb kit (Santa Clara, CA). Then DNA libraries were sequenced on the HiSeq2000/2500 sequencer according to the manufacturer\'s instructions (Illumina, San Diego, CA). The data analysis method followed the pipeline established in house (Yang et al., [2019](#mgg31144-bib-0020){ref-type="ref"}). Human Phenotype Ontology (HPO) was converted and integrated into the PhenoPro pipeline, a method developed by our team (Li et al., [2019](#mgg31144-bib-0011){ref-type="ref"}). The criteria of the molecular diagnosis followed the American College of Medical Genetics (ACMG) guidelines (Matthijs et al., [2016](#mgg31144-bib-0013){ref-type="ref"}). The distribution of variant heterozygosity on each chromosome was calculated to scan the UPD event. UPD was detected using "B Allele Frequency" (BAF) (van Riet et al., [2018](#mgg31144-bib-0019){ref-type="ref"}).

The variant of *PREPL* (NM_006036.4) was confirmed by Sanger sequencing using ABI 3,730 Genetic Analyzer (Applied Biosystems). Paired primers were designed by Primer3 website: primer‐*F* (5′‐TTAATGATACTTGGTGGCCTAAATAAA‐3′) and primer‐R (5′‐GCTTTCAGTAAATGGGAGCTGA‐3′).

Agilent SurePrint G3 comparative genomic hybridization (CGH) and SNP 4 × 180K microarray (Agilent Technologies, USA) was used to confirm the UPD(2) following the manufacturer\'s instructions. We used Agilent Cytogenomics software package for CNVs and loss of heterozygosity (LOH) calling and visualization.

2.2. Patient {#mgg31144-sec-0008}
------------

The proband is a 6‐month‐old Chinese Han female infant who is the first child of healthy non‐consanguineous parents. She was born after an uneventful full‐term pregnancy with a birth weight of 2.8 kg. She presented with neonatal hypotonia and feeding difficulties, and was suspected of spinal muscular atrophy (SMA) in the local hospital. She was referred to our hospital because of poor nursing, weak crying, and delayed developmental milestones. Her motor examination demonstrated low muscle tone and muscle strength (4/5, MRC scale) for all major muscle groups in the upper and lower extremities. Needle EMG showed myopathic changes. The test results of liver function, thyroid function, blood ammonia, liquid chromatography‐tandem mass spectrometry analysis of blood and urine and SMA‐ multiplex ligation‐dependent probe amplification (MLPA) were all normal. She was diagnosed with CMS22 at the age of 6 months and treated with pyridostigmine (15 mg, three times a day, per orally) at the age of 8 months. At the last follow‐up when she was 9 months, she was better than before in feeding and could raise her head steadily, rollover independently, and stand with support.

Pretest counseling was performed in the clinic. Informed consent was signed by the parents. The criteria of genetic testing received approval from the ethics committees of the Children\'s Hospital, Fudan University (2015--130).

3. RESULTS {#mgg31144-sec-0009}
==========

Trio‐WES data showed that 96.70% (1668/1725) variants on chromosome 2 had a BAF higher than 0.95 inherited from mother, revealing the LOH of the proband and suggesting UPD(2)mat (Figure [1](#mgg31144-fig-0001){ref-type="fig"}a). Meanwhile, a novel homozygous frameshift mutation in *PREPL* (c.1282_1285delTTTG, p.Phe428Argfs\*18) was detected in the proband, her mother was heterozygous and her father was normal (Figure [1](#mgg31144-fig-0001){ref-type="fig"}b). This variant was confirmed by Sanger sequencing (Figure [1](#mgg31144-fig-0001){ref-type="fig"}c). It has never been reported in the 1,000 Genome Project, the EXAC or the gnomAD database, and it is the only record in our in‐house database, which contains more than 30 000 exome sequencing data of patients. The frameshift variant may form truncated proteins, which lead to loss of the peptidase S9 prolyl oligopeptidase catalytic domain. Three of the eight reported truncating mutations (including nonsense and frameshift mutations) are located after this frameshift variant (Figure [2](#mgg31144-fig-0002){ref-type="fig"}a). Therefore, this frameshift variant was classified as pathogenic.

![Results of genetic tests in our patient. (a) Trio‐WES identifies that 96.70% (1668/1725) variants on chromosome 2 are homozygous and inherited from the mother, suggesting that the proband has UPD(2)mat. (b) A novel homozygous frameshift variant on *PREPL* (c.1282_1285delTTTG) is detected in the proband. Her mother is heterozygous and her father is normal. (c) The variant is confirmed by Sanger sequencing. D Array‐CGH identifies UPD(2) by showing the LOH across the whole chromosome 2](MGG3-8-e1144-g001){#mgg31144-fig-0001}

![Summary of pathogenic variants and gross deletions in *PREPL.* (a) Nine truncating mutations on *PREPL*. The red shows the novel frameshift mutation in our patient. (b) The size and location of the six reported gross deletions in CMS22 patients](MGG3-8-e1144-g002){#mgg31144-fig-0002}

Trio‐WES did not identify other pathogenic or likely pathogenic variants associated with the clinical features or other inherited diseases. Data from array‐CGH showed complete UPD(2) by showing LOH across the entire chromosome 2, which supported the diagnosis of UPD(2). Array‐CGH did not reveal any other pathogenic CNVs (Figure [1](#mgg31144-fig-0001){ref-type="fig"}d).

In combination of the clinical phenotype (neonatal hypotonia, muscular weakness, and feeding difficulties) and the molecular genetic finding, the proband was diagnosed with CMS22 caused by a *PREPL* novel homozygous pathogenic variation with UPD(2)mat.

4. DISCUSSION {#mgg31144-sec-0010}
=============

The *PREPL* gene is one of the genes affected in contiguous gene deletion syndromes at 2p21 (Bartholdi et al., [2013](#mgg31144-bib-0001){ref-type="ref"}). Isolated PREPL deficiency results in CMS22 (OMIM 616,224). PREPL is localized in the cytosol with highest expression in brain, kidney, and muscle, in decreasing order (Martens et al., [2006](#mgg31144-bib-0012){ref-type="ref"}). It is an effector of clathrin‐associated adaptor protein 1 (AP‐1) to take part in the regulation of AP‐1 membrane binding (Radhakrishnan, Baltes, Creemers, & Schu, [2013](#mgg31144-bib-0014){ref-type="ref"}), which is required for normal trafficking of the vesicular ACh transporter between the synaptic vesicle and the cytosol (Kim & Hersh, [2004](#mgg31144-bib-0008){ref-type="ref"}). In a CMS22 patient, Régal et al found the absence of PREPL in frozen muscle fibers and at the endplates (EPs) in the neuromuscular junction, but EPs showed normal ACh receptor and ACh enzyme. However, microelectrode studies showed reduced miniature endplates potential (MEPP) and miniature endplates current (MEPC) amplitudes and decreased quantal release. Hence, Régal et al hypothesized that the absence of PREPL may affect function of AP‐1 and lead to reduced filling of the synaptic vesicles with ACh (Regal et al., [2014](#mgg31144-bib-0016){ref-type="ref"}). Hence, we speculate that pyridostigmine, as a cholinesterase inhibitor, can inhibit the decomposition of ACh, and relieve the neuromuscular symptoms of patients. These may provide a potential explanation for the pyridostigmine treatment of CMS22.

Nine patients with CMS22 have been reported including our patient (Table [1](#mgg31144-tbl-0001){ref-type="table"}). There were seven females and two males with the symptoms onset in neonatal period (9/9). However, the age of diagnosis varied from 6 months to 25 years. Our patient was the youngest one who was diagnosed with CMS22 at 6 months. The CMS22 patient may respond to pyridostigmine in the first year of life (Regal et al., [2014](#mgg31144-bib-0016){ref-type="ref"}). Patient 7 were treated with pyridostigmine before 1 year old and turned out to have a positive response, while patient 8 started treatment at 14 months without clinical response. Our patient (patient 1) started pyridostigmine treatment at 8 months and had a positive response. Interestingly, other 6 patients without pyridostigmine treatment and patient 8 all showed symptom improvement after one year old. Although the rationale of spontaneous improvement of symptoms is not clear, it is noticeable that the positive response to pyridostigmine seemingly appeared when the patients were performed treatment before 1 year old (patient 1 and 7), and the earlier the treatment, the better the response (patient 7 with a strongly positive response, better than our patient). If treated after 1 year old, the effect of pyridostigmine treatment seems to be weak, and the symptom may start to relieve.

###### 

Clinical characteristic and molecular genetic features of nine CMS22 patients

<table><thead><tr class="header"><th>Feature/Patient</th><th>1</th><th>2</th><th>3</th><th>4</th><th>5</th><th>6</th><th>7</th><th>8</th><th>9</th><th>Total</th></tr></thead><tbody><tr class="odd"><td>PMID</td><td>This study</td><td>28,726,805 (IPD1)</td><td>28,726,805 (IPD2)</td><td>28,726,805 (IPD3)</td><td>28,726,805 (IPD4)</td><td>28,726,805 (IPD5)</td><td>24,610,330</td><td>29,913,539</td><td>29,483,676</td><td>NA</td></tr><tr class="even"><td>Gender</td><td>F</td><td>F</td><td>F</td><td>M</td><td>F</td><td>M</td><td>F</td><td>F</td><td>F</td><td>7F, 2M</td></tr><tr class="odd"><td>Phenotype onset</td><td>Neonate</td><td>Neonate</td><td>Neonate</td><td>Neonate</td><td>Neonate</td><td>Neonate</td><td>Neonate</td><td>Neonate</td><td>Neonate</td><td>9/9 Neonate</td></tr><tr class="even"><td>Age at diagnosis</td><td>6 months</td><td>15 years</td><td>1 years</td><td>2 years</td><td>25 years</td><td>3 years 6 months</td><td>NA</td><td>NA</td><td>9 years</td><td>6 months−25 years</td></tr><tr class="odd"><td>Last evaluated age</td><td>9 months</td><td>17 years</td><td>2 years 5 months</td><td>2 years 10 months</td><td>27 years</td><td>3 years 8 months</td><td>17 months</td><td>3 years</td><td>10 years</td><td>9 months−27 years</td></tr><tr class="even"><td>Failure to thrive</td><td>+</td><td>+</td><td>+</td><td>−</td><td>−</td><td>−</td><td>NA</td><td>+</td><td>+</td><td>5/8</td></tr><tr class="odd"><td>GH deficiency</td><td>NA</td><td>+</td><td>+</td><td>+</td><td>−</td><td>−</td><td>+</td><td>+</td><td>NA</td><td>5/7</td></tr><tr class="even"><td>PWS/SMA test</td><td>SMA (−)</td><td>PWS (−)</td><td>PWS (−)</td><td>PWS (−)</td><td>PWS (−)</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>5/9</td></tr><tr class="odd"><td>Cystinuria</td><td>−</td><td>−</td><td>−</td><td>−</td><td>−</td><td>+</td><td>−</td><td>NA</td><td>NA</td><td>−:6/+:1/NA:2</td></tr><tr class="even"><td>Neonatal hypotonia</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>9/9</td></tr><tr class="odd"><td>Muscular weakness</td><td>+</td><td>−</td><td>+</td><td>−</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>7/9</td></tr><tr class="even"><td>Feeding difficulties</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>‐</td><td>+</td><td>+</td><td>+</td><td>8/9</td></tr><tr class="odd"><td>Ptosis</td><td>−</td><td>−</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>−</td><td>+</td><td>6/9</td></tr><tr class="even"><td>Walking age</td><td>NA</td><td>21 months</td><td>23 months</td><td>22 months</td><td>19 months</td><td>24 months</td><td>17 months</td><td>26 months</td><td>27 months</td><td>17−27 months</td></tr><tr class="odd"><td>Childhood‐onset obesity</td><td>NA</td><td>+</td><td>−</td><td>−</td><td>+</td><td>−</td><td>NA</td><td>NA</td><td>+</td><td>3/6</td></tr><tr class="even"><td>Cognitive/behavioral problems</td><td>NA</td><td>−</td><td>+(DI 69）</td><td>+</td><td>+(IQ 64）</td><td>+(IQ 80）</td><td>NA</td><td>+(mild)</td><td>+(IQ 49）</td><td>6/7</td></tr><tr class="odd"><td><p>Pyridostigmine</p><p>treatment</p></td><td>Yes, started at 8 months with a positive response</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>Yes, started at age of 11 weeks with a strongly positive response</td><td>Yes, started at 14 months without clinical response</td><td>NA</td><td>3/9</td></tr><tr class="even"><td>Improvement of symptoms (age)</td><td>+ (9 months)</td><td>+ (6.5 years)</td><td>+ (13 months)</td><td>+ (18 months)</td><td>+ (1 year)</td><td>NA</td><td>+ (11 weeks)</td><td>+ (2 years)</td><td>+ (3 years)</td><td>8/8</td></tr><tr class="odd"><td>Zygosity</td><td>Homozygous du to UPD(2)mat</td><td>Homozygous</td><td>Compound heterozygous</td><td>Compound heterozygous</td><td>Compound heterozygous</td><td>Compound heterozygous</td><td>Compound heterozygous</td><td>Compound heterozygous</td><td>Homozygous</td><td>UPD(2)mat:1/Hom:2/Compound Het:6</td></tr><tr class="even"><td><em>PREPL</em> mutation</td><td>c.1282_1285delTTTG, p.Phe428Argfs*18</td><td>NA</td><td>c.358_361delTTTG, p.Val121Ilefs*121</td><td>c.1604T&gt;G, p.Leu535Ter</td><td>c.883 C&gt;T, p.Arg295Ter</td><td>c.1156−1G&gt;A, p.Leu386_Lys451del</td><td>c.807delT, p.Met270Ter</td><td>c.1529 + 1G&gt;A; c.1784delinsAA, p.Thr595Lysfs*19</td><td>c.342delA, p.Val115Leufs*39)</td><td>Nine different mutations</td></tr><tr class="odd"><td><em>PREPL</em> deletion</td><td>NA</td><td><em>PREPL</em> exon 5–10</td><td><em>PREPL</em> exon 7–8</td><td><em>SLC3A1</em> exon10‐<em>PREPL</em> exon10</td><td><em>PREPL</em> exon12‐<em>CAMKMT</em> exon2</td><td><em>SLC3A1</em> exon 7‐<em>CAMKMT</em> exon 2</td><td><em>SLC3A1</em> exon5‐<em>PREPL</em> exon9</td><td>NA</td><td>NA</td><td>Six different deletions</td></tr></tbody></table>

Abbreviations: +, positive; −, negative; DI, developmental index; IQ, intelligence quotient; Het, heterozygous; Hom, homozygous; F, female; M, male; GH, growth hormone; NA, not applicable.
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In total, nine mutations and six gross deletions in *PREPL* have been detected currently (Figure [2](#mgg31144-fig-0002){ref-type="fig"}). The nine mutations are all truncating mutations which include four frameshifts (p.Val121Ilefs\*121, p.Thr595Lysfs\*19, p.Val115Leufs\*39, and p.Phe428Argfs\*18), three nonsense mutations (p.Leu535Ter，p.Arg295Ter, and p.Met270Ter), and two splicing mutations (c.1156‐1G\>A and c.1529+1G\>A). The eight reported mutations all locate in the protein domains (peptidase S9A N‐terminal domain or peptidase S9 prolyl oligopeptidase catalytic domain). The novel frameshift mutation at exon 8 detected in our study (p.Phe428Argfs\*18) do not locate in the protein domains. But, it could lead to the loss of the peptidase S9 prolyl oligopeptidase catalytic domain (Figure [2](#mgg31144-fig-0002){ref-type="fig"}a). In the six patients with gross deletions, patient 2 and 3 with *PREPL* single gene deletion, other 4 involve contiguous genes of *SLC3A1* and *CAMKMT* (Figure [2](#mgg31144-fig-0002){ref-type="fig"}b).

UPD can be associated with human diseases through three primary mechanisms: imprinting, homozygosity for an autosomal recessive trait, or mosaic aneuploidy (Siegel & Slavotinek, [2005](#mgg31144-bib-0017){ref-type="ref"}). It is worth mentioning that, both UPD(2)mat and UPD(2)pat have been reported in individuals with normal phenotype (Bernasconi et al., [1996](#mgg31144-bib-0002){ref-type="ref"}; Keller et al., [2009](#mgg31144-bib-0007){ref-type="ref"}), suggesting that the imprinting is not the pathogenic mechanism for patients with UPD2 presenting phenotype.

The clinical features of CMS22 are similar to those of Prader‐Willi syndrome (PWS), such as neonatal hypotonia, feeding difficulties, the improvement of symptoms after 1 year old and childhood‐onset obesity. So, four of nine patients were firstly suspected of PWS. Our infantile patient showed neonatal hypotonia and feeding difficulties, and she was firstly suspected of SMA. Therefore, CMS22 should be carefully considered by the pediatrician when the common causes including PWS and SMA were negative. The timely genetic test is crucial to the early diagnosis of CMS22.

In summary, we report the first and the youngest case of CMS22 for UPD(2)mat with a novel homozygous frameshift variant in *PREPL*, which expands the mutation spectrum and further delineates the phenotype and genotype of CMS22.
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